MOR-106
Based on 1 Customer Validation
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.42%
- CAS No.: 2304625-87-2
- Masse moléculaire:144.02 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 lambda
Human
|
NF-κB |
IL-17C |
MOR-106 (0.00001-1 nM, 30 min) potently blocks the interaction of human (IC50 = 59 pM) IL-17C and mouse (IC50 = 55 pM) IL-17C to IL-17RE[1].
MOR-106 (0.0001-1 μg/mL, 30 min) significantly inhibits IL-17C induced activation of NF-κB signaling pathway in NIH3T3 cells[1].
MOR-106 (0.001-1 μg/mL, 48 h) significantly inhibits the expression of DEFB4A and CSF3 induced by IL-17C and TNF-α in human and mouse primary keratinocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human and mouse primary keratinocytes
-
Concentration:0.001-1 μg/mL
-
Incubation Time:48 h
-
Result:Significantly reduced the levels of DEFB4A and CSF3.
MOR-106 (0.4-50 mg/kg, i.p., 3 days before, at the start, and 4 days after the first application of MC903) effectively alleviates MC903 induced atopic dermatitis and atopic eczema in female BALB/c mice[1][2].
MOR-106 (3 and 30 mg/kg, i.p., twice weekly, for 6 weeks) alleviates spontaneous atopic dermatitis in Flaky tail mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:IL-23 (1 μg, for 4 consecutive days) injeceted female BALB/c mice (8 weeks)[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), 3 days before and just before the first injection of IL-23
-
Result:Significantly reduced ear swelling and epidermal thickening.
Reduced the expression of inflammatory factors such as IL-17A, IL-22, IL-1β, LCN2, S100A8 and S100A9.
-
Animal Model:
-
Dosage:0.4, 2, 10 and 50 mg/kg
-
Administration:Intraperitoneal injection (i.p.), 3 days before, at the start, and 4 days after the first application of MC903
-
Result:Dose dependently reduced ear swelling and epidermal thickening.
Reduced TSLP, IL-33, and CCL17 levels.
Significantly reduced skin infiltration of T cells, eosinophils, and neutrophils.
-
Animal Model:Flaky tail mice on a congenic C57BL/6J background[1]
-
Dosage:3 and 30 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice weekly for 6 weeks
-
Result:Significantly reduced skin inflammation score.
Reduced the number of mast cells and serum IgE levels.
Reduced the expression of IL-4, IL-17A, CCL17 and IFN-γ.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized Human IL-17c, His Tag can bind MOR-106. The EC50 for this effect is 7.102 ng/mL.
Chemical Information
-
CAS No. 2304625-87-2
-
Appearance Liquid
-
Masse moléculaire 144.02 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
MOR12743; MOR03207
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Vandeghinste N, et al. Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. J Invest Dermatol. 2018 Jul;138(7):1555-1563. [Content Brief]
[2]. Lauffer F, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):800-809. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MOR-106 Related Classifications
HY-P991598 Related Classifications
Powered by Bioz